Search results
Results From The WOW.Com Content Network
Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. [6][7][8] It is used an alternative to warfarin to prevent blood clots following hip or knee replacement and in those with a ...
According to the manufacturer of Eliquis, in 2024, the list price for a 30-day supply of Eliquis is $594, but people on Medicare pay, on average, $55 per month. And 5 out of 10 people on Medicare ...
Andexanet alfa is used to stop life-threatening or uncontrollable bleeding in people who are taking rivaroxaban or apixaban. [8] Studies in healthy volunteers show that the molecule binds factor Xa inhibitors and counters their anti-Xa-activity. [11] The first published clinical trial was a prospective, open label, single group study. [12]
Rivaroxaban. 2 / 3 metabolized in liver and 1 / 3 eliminated unchanged [4] Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial ...
The list price of Merck's diabetes drug Januvia will be slashed to $113 for a 30-day supply from $527 as of 2023. Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer, will cost $231 for ...
The article Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban) originally appeared on Fool.com. Try any of our Foolish newsletter services free for 30 days .
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union Army veteran of the American Civil War for whom the company was later named.
The blood thinner Eliquis is a top seller for Bristol Myers Squibb. CMS Medicare Part D data shows the government spent $15 billion in 2022 on the drug out of a total of $46.4 billion spent on ...